On the other hand, antigen-loaded tolDC-GAD65 and tolDC-OVA prepared in serum-supplemented conditions did not substantially decreased diabetes incidence compared to the Control group (75 and 62.5% diabetic animals, respectively) (Figure 4). This evidence concerns the gene GAD2 and diabetes mellitus.